Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives.
Pauli
G
G
Hôpitaux Universitaires and INSERM U-425, Strasbourg, France.
Purohit
A
A
Oster
J P
JP
de Blay
F
F
Vrtala
S
S
Niederberger
V
V
Kraft
D
D
Valenta
R
R
D000485:Allergens / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D052179:Antigens, Plant; D003888:Desensitization, Immunologic; D005818:Genetic Engineering; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000276:immunology; D010940:Plant Proteins / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use
D000485:Allergens; D052179:Antigens, Plant; D010940:Plant Proteins; D011994:Recombinant Proteins; C061312:Bet v 1 allergen, Betula